MiR-150 is a Negative Independent Prognostic Biomarker for Primary Gastrointestinal Diffuse Large B-cell Lymphoma
Overview
Authors
Affiliations
A number of studies suggest an association between miRNAs and diffuse large B-cell lymphoma (DLBCL). The present study aimed to investigate the prognostic value of microRNA (miR-150) in primary gastrointestinal (PGI)-DLBCL, by assessing the association between miR-150 expression and clinicopathological characteristics in patients with PGI-DLBCL. A total of 84 patients diagnosed with PGI-DLBCL were recruited and both tumor and adjacent non-tumor tissue samples were collected. miR-150 expression was assessed via reverse transcription-quantitative (RT-q)PCR analysis. The results demonstrated that miR-150 expression was significantly lower in PGI-DLBCL tissues compared with adjacent non-tumor tissues. Furthermore, receiver operating characteristic (ROC) curve analysis indicated that the optimal cut-off value of miR-150 for predicting survival was 8.965 with high sensitivity (79.8%) and specificity (77.1%). Patients were divided into two groups according to this cut-off value, as follows: High (n=18) and low expression (n=66) groups. Low miR-150 expression was significantly associated with clinical stage, International Prognostic Index (IPI), Eastern Cooperative Oncology Group status and use of rituximab. RT-qPCR analysis demonstrated that miR-150 expression was significantly lower in patients with high IPI scores compared with patients with low IPI scores. Downregulated miR-150 expression was significantly associated with shorter overall survival (OS) time and progression-free survival (PFS) time in patients with PGI-DLBCL. Furthermore, miR-150 level and IPI score were identified as two risk factors for OS and PFS. The diagnostic value of miR-150 was evaluated via ROC curve analysis, with an area under the curve value of 0.882. Taken together, the results of the present study suggest that miR-150 is a potential diagnostic marker of PGI-DLBCL, and may also serve as a useful prognostic factor for survival outcomes in patients with PGI-DLBCL.
Wagiu Basrowi R, Sundjaya T, Pratiwi D, Amalia N, Tandi Y, Syafaatulloh M Front Nutr. 2025; 12:1535498.
PMID: 39931366 PMC: 11807793. DOI: 10.3389/fnut.2025.1535498.
Khanmohammadi S, Masrour M, Fallahtafti P, Hasani F Cancer Rep (Hoboken). 2025; 8(1):e70070.
PMID: 39854617 PMC: 11760998. DOI: 10.1002/cnr2.70070.
Multiple functions and regulatory network of miR-150 in B lymphocyte-related diseases.
Hu Y, Li Q, Wang P, Li X, Hu Z Front Oncol. 2023; 13:1140813.
PMID: 37182123 PMC: 10172652. DOI: 10.3389/fonc.2023.1140813.
Fernandes M, Marques H, Teixeira A, Medeiros R Int J Mol Sci. 2022; 23(1).
PMID: 35008626 PMC: 8745130. DOI: 10.3390/ijms23010201.
Primary gastric non-Hodgkin lymphomas: Recent advances regarding disease pathogenesis and treatment.
Diamantidis M, Papaioannou M, Hatjiharissi E World J Gastroenterol. 2021; 27(35):5932-5945.
PMID: 34629810 PMC: 8475005. DOI: 10.3748/wjg.v27.i35.5932.